Immuno-Oncology

A subgroup analysis found that the addition of durvalumab to chemotherapy resulted in maintained overall survival benefit in patients with advanced biliary tract cancer, regardless of primary tumor location.

Data from the CheckMate 648 trial informed the FDA’s recent approval of 2 nivolumab combinations for esophageal squamous cell carcinoma. A 1-year follow-up analysis highlighted key safety and time-to-event data surrounding immune-related toxicities.

The FDA has approved lisocabtagene maraleucel as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma.

This year’s congress showcased strategies for communicating sensitive topics, patient experiences with immunotherapy treatments, updates in the utility of medical cannabis, and more.

A study analyzing the long-term adrenal insufficiency outcomes of patients receiving immune checkpoint inhibition therapy found that secondary insufficiency was more common than primary in this patient population.

Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.

Relatlimab, a human LAG-3 blocking antibody, plus nivolumab, elicited superior progression-free survival in patients with advanced melanoma compared to nivolumab alone.

Updates to the NCCN guidelines for patients with resectable early-stage NSCLC now include neoadjuvant and adjuvant regimens with chemotherapy, immunotherapy, and targeted therapies, which promise to change biomarker testing practice.

Patients with cancer were reported to have mixed expectations with immunotherapy as part of their oncology treatment.

Oncology nurses found that the use of a flexible catheter for subcutaneous immunotherapy is linked with increased safety and satisfaction.

The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.

An improved progression-free survival benefit was observed in patients with stage III unresectable or stage IV melanoma who received nivolumab plus ipilimumab.

An update from the phase 3 SKYSCRAPER-02 trial found that tiragolumab to atezolizumab did not significantly improve progression-free survival in extensive-stage small cell lung cancer.

La-Urshala Brock, FNP-BC, CNM, RNFA, discusses effective toxicity management for patients with breast cancer receiving pembrolizumab.

Nivolumab combined with chemotherapy is now approved in the resectable non–small cell lung cancer setting.

The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.

Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.

Adding sacituzumab govitecan to second-line pembrolizumab garnered promising antitumor activity among patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

A City of Hope expert underscores the benefit of using antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint blockade in early-stage and metastatic breast cancer.

Mark Honor, PA-C, highlights best adverse event management practices for patients undergoing chemotherapy and immune-based treatment.

An expert from the University of Colorado (UC Health) comments on ongoing clinical trials which promise to shake up the treatment paradigm of endometrial cancer.

Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.

New data suggest that patients undergoing immunotherapy achieved better survival outcomes after reporting cutaneous immune-related adverse events.

Pending FDA approval, the dual immunotherapy combination could provide patients with a new treatment option which would not require any further safety requirements prior to initiation.

New data support increased fiber consumption and decreased probiotic use among patients receiving immunotherapy.

A triplet regimen of tucatinib, trastuzumab, and capecitabine helped patients with HER2-positive metastatic breast cancer and brain metastases live longer with reduced disease progression compared with trastuzumab and capecitabine alone.

A novel regimen of relatlimab, an LAG-3 inhibitor, plus nivolumab doubled progression-free survival in patients with untreated, advanced melanoma.

Event co-chair, Syma Iqbal, MD, discusses key points from a recent OncLive® Institutional Perspectives in Cancer webinar, which focused on the evolving landscapes in gastrointestinal cancer.

A seroconversion rate of 94% was identified in a diverse cohort of patients with cancer who had received the COVID-19 vaccine.

Survival outcomes in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma were improved when nivolumab was added alongside either ipilimumab or chemotherapy.